CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Simvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00053599
NCT00053599Phase 3Completed
CompareCT.gov

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease

National Institute on Aging (NIA)·interventional·Posted Feb 4, 2003·Updated Jul 28, 2009

In Brief

A Phase 3 clinical trial evaluating Simvastatin for Alzheimer Disease. Completed, across 44 sites.

Detailed Summary

CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsAlzheimer's Disease Cooperative Study (ADCS)

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 4, 2003
Enrollment StartDec 1, 2002
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 23.4 years ago

Interventions

Simvastatindrug